These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 23302321)

  • 1. [Molecular pathology of lung cancer: key to personalized medicine].
    Cheng L; Li Y; Zhang SB; Teng XD
    Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):715-20. PubMed ID: 23302321
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular alterations in non-small cell lung carcinomas of the young.
    VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
    Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Significance of molecular technology in diagnosis and therapy of non-small-cell lung cancer].
    Chen XX; Zhou CC
    Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):570-2. PubMed ID: 23157756
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeted treatment for lung cancer could be possible due to identification of nonuniform genetic mutations.
    Jones S
    Pharmacogenomics; 2014 May; 15(7):903-4. PubMed ID: 25090664
    [No Abstract]   [Full Text] [Related]  

  • 5. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
    Roberts PJ; Stinchcombe TE; Der CJ; Socinski MA
    J Clin Oncol; 2010 Nov; 28(31):4769-77. PubMed ID: 20921461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer.
    Cottini F; Lautenschlaeger T
    Cancer J; 2013; 19(3):263-71. PubMed ID: 23708073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Gene mutation (KRAS, BRAF, PIK3CA) and clinical benefit of anti-EGFR antibody].
    Ueno T; Moriwaki T; Hyodo I
    Nihon Rinsho; 2011 Apr; 69 Suppl 3():477-81. PubMed ID: 22214007
    [No Abstract]   [Full Text] [Related]  

  • 8. EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer.
    de Mello RA; Madureira P; Carvalho LS; Araújo A; O'Brien M; Popat S
    Pharmacogenomics; 2013 Nov; 14(14):1765-77. PubMed ID: 24192124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
    Khambata-Ford S; Harbison CT; Hart LL; Awad M; Xu LA; Horak CE; Dakhil S; Hermann RC; Lynch TJ; Weber MR
    J Clin Oncol; 2010 Feb; 28(6):918-27. PubMed ID: 20100958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of cetuximab after failure of gefitinib in patients with advanced non-small-cell lung cancer.
    Wu JY; Yang CH; Hsu YC; Yu CJ; Chang SH; Shih JY; Yang PC
    Clin Lung Cancer; 2010 Jul; 11(4):257-63. PubMed ID: 20630828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"?
    Cremolini C; Loupakis F; Ruzzo A; Perrone G; Rulli E; Vincenzi B; Tonini G; Graziano F; Muda AO; Falcone A
    J Clin Oncol; 2010 Apr; 28(11):e173-4; author reply e175-6. PubMed ID: 20177018
    [No Abstract]   [Full Text] [Related]  

  • 12. ALK, lung cancer, and personalized therapy: portent of the future?
    Garber K
    J Natl Cancer Inst; 2010 May; 102(10):672-5. PubMed ID: 20460631
    [No Abstract]   [Full Text] [Related]  

  • 13. Molecular profiling in non-small cell lung cancer: a step toward personalized medicine.
    Raparia K; Villa C; DeCamp MM; Patel JD; Mehta MP
    Arch Pathol Lab Med; 2013 Apr; 137(4):481-91. PubMed ID: 23544937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review.
    Malapelle U; Bellevicine C; Zeppa P; Palombini L; Troncone G
    Diagn Cytopathol; 2011 Sep; 39(9):703-10. PubMed ID: 21837660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.
    O'Byrne KJ; Gatzemeier U; Bondarenko I; Barrios C; Eschbach C; Martens UM; Hotko Y; Kortsik C; Paz-Ares L; Pereira JR; von Pawel J; Ramlau R; Roh JK; Yu CT; Stroh C; Celik I; Schueler A; Pirker R
    Lancet Oncol; 2011 Aug; 12(8):795-805. PubMed ID: 21782507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
    Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F
    J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
    Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
    J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma.
    Matsuura S; Shinmura K; Kamo T; Igarashi H; Maruyama K; Tajima M; Ogawa H; Tanahashi M; Niwa H; Funai K; Kohno T; Suda T; Sugimura H
    Oncol Rep; 2013 Oct; 30(4):1675-80. PubMed ID: 23877438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance therapy comes of age for non-small-cell lung cancer, but at what cost?
    Shepherd FA
    J Clin Oncol; 2011 Nov; 29(31):4068-70. PubMed ID: 21969515
    [No Abstract]   [Full Text] [Related]  

  • 20. Histology matters: individualizing treatment in non-small cell lung cancer.
    Neal JW
    Oncologist; 2010; 15(1):3-5. PubMed ID: 20086166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.